Now showing items 1-2 of 2

    • Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. 

      Hudeček, J; Voorwerk, L; van Seijen, M; Nederlof, I; de Maaker, M; van den Berg, J; van de Vijver, KK; Sikorska, K; Adams, S; Demaria, S; Viale, G; Nielsen, TO; Badve, SS; Michiels, S; Symmans, WF; Sotiriou, C; Rimm, DL; Hewitt, SM; Denkert, C; Loibl, S; Loi, S; Bartlett, JMS; Pruneri, G; Dillon, DA; Cheang, MCU; Tutt, A; Hall, JA; Kos, Z; Salgado, R; Kok, M; Horlings, HM; International Immuno-Oncology Biomarker Working Group (2020-01)
      Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic triple-negative breast cancer (TNBC). To incorporate sTILs into clinical trials and diagnostics, ...
    • Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. 

      Kos, Z; Roblin, E; Kim, RS; Michiels, S; Gallas, BD; Chen, W; van de Vijver, KK; Goel, S; Adams, S; Demaria, S; Viale, G; Nielsen, TO; Badve, SS; Symmans, WF; Sotiriou, C; Rimm, DL; Hewitt, S; Denkert, C; Loibl, S; Luen, SJ; Bartlett, JMS; Savas, P; Pruneri, G; Dillon, DA; Cheang, MCU; Tutt, A; Hall, JA; Kok, M; Horlings, HM; Madabhushi, A; van der Laak, J; Ciompi, F; Laenkholm, A-V; Bellolio, E; Gruosso, T; Fox, SB; Araya, JC; Floris, G; Hudeček, J; Voorwerk, L; Beck, AH; Kerner, J; Larsimont, D; Declercq, S; Van den Eynden, G; Pusztai, L; Ehinger, A; Yang, W; AbdulJabbar, K; Yuan, Y; Singh, R; Hiley, C; Bakir, MA; Lazar, AJ; Naber, S; Wienert, S; Castillo, M; Curigliano, G; Dieci, M-V; André, F; Swanton, C; Reis-Filho, J; Sparano, J; Balslev, E; Chen, I-C; Stovgaard, EIS; Pogue-Geile, K; Blenman, KRM; Penault-Llorca, F; Schnitt, S; Lakhani, SR; Vincent-Salomon, A; Rojo, F; Braybrooke, JP; Hanna, MG; Soler-Monsó, MT; Bethmann, D; Castaneda, CA; Willard-Gallo, K; Sharma, A; Lien, H-C; Fineberg, S; Thagaard, J; Comerma, L; Gonzalez-Ericsson, P; Brogi, E; Loi, S; Saltz, J; Klaushen, F; Cooper, L; Amgad, M; Moore, DA; Salgado, R; International Immuno-Oncology Biomarker Working Group (2020-01)
      Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible ...